Find Clinical Drug Pipeline Developments & Deals for PEN-866

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PEN-866

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 13, 2020

            Details:

            PEN-866 demonstrates a favorable therapeutic index with a broad therapeutic range, was well tolerated and showed evidence of anti-tumor activity in patients with advanced solid tumor malignancies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PEN-866,7-Ethyl-10-Hydroxycamptothecin

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 21, 2020

            Details:

            PEN-866 is the initial clinical program from Tarveda’s HSP90 binding miniature drug conjugate platform, designed to bind to activated Heat Shock Protein 90 (HSP90) in treating solid tumors.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PEN-866

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Organovo Holdings

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Termination April 07, 2020

            Details:

            Unanticipated late opposition by major Organovo stockholder results in termination of proposed merger agreement.